BOONTON, N.J., Jan. 23, 2017 /PRNewswire/ -- Enteris BioPharma, Inc., announced today the initiation of a feasibility study agreement with Sanofi to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence, to develop an oral formulation of one of Sanofi’s preclinical stage peptides.
Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, remarked, “Our agreement with Sanofi is further validation of the tremendous value our Peptelligence platform program offers in the therapeutic peptide field. We are excited to work with an industry leader like Sanofi.”
About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. Enteris’ proprietary oral delivery technology Peptelligence - has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Enteris BioPharma’s most advanced internal product candidate, Ovarest, an oral peptide for endometriosis will begin Phase 2A trials in the next quarter.
For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit http://www.EnterisBioPharma.com.
For Enteris BioPharma:
Brian Zietsman, President & CFO
+1.973.453.3527
Enteris Media Relations:
Jason Rando / Amy Wheeler
Tiberend Strategic Advisors, Inc.
+1.212.827.0020
jrando@tiberend.com
awheeler@tiberend.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enteris-biopharma-enters-agreement-with-sanofi-to-develop-investigational-oral-therapeutic-for-type-2-diabetes-300394571.html
SOURCE Enteris BioPharma, Inc.
